KRAS gene and K-Ras protein in cell signaling
Pharma licensing assets from China has become the main source for Western drug developers, with Evaluate projecting China-based deals will exceed two-thirds of industry value this year. The shift prompts concerns about hollowing out U.S. biotech capacity while supporters argue it accelerates patient access to new medicines.
The FDA has approved daraxonrasib, sold as Rasonque, for metastatic pancreatic cancer in patients who have received prior therapy or cannot take combination chemotherapy. Clinical trial data show median survival of 13.2 months versus 6.7 months with chemotherapy. Revolution Medicines has priced a 30‑day supply at about $39,800 and is offering patient assistance.